BACKGROUND: Sacituzumab govitecan (IMMU-132), an antitrophoblastic cell-surface antigen (anti-Trop-2) humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU-132 at doses of 8 or 10 mg/kg in patients with diverse advanced epithelial cancers. METHODS: Patients who had multiple prior therapies received IMMU-132 on days 1 and 8 of 21-day treatment cycles. Trop-2 staining of archived tumor specimens, clearance of IMMU-132 and its constituents (ie, immunoglobulin G [IgG], SN-38 [a camptothecin, the active component of irinotecan], and glucuronidated SN-38 [SN-38G]), antibody responses, and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) levels were determined. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0, and responses were assessed using Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Patients with diverse metastatic cancers who received IMMU-132 at 8 mg/kg (n 5 81) and 10 mg/kg (n 5 97) were examined. Trop-2 was positive in 93% of the available specimens. IMMU-132 cleared with a half-life of approximately 11 to 14 hours, reflecting the release of SN-38 from the conjugate; IgG cleared more slowly (half-life, approximately 103-114 hours). Most SN-38 in the serum (>95%) was bound to IgG. SN-38G concentrations were lower than SN-38 concentrations. Dose-limiting neutropenia after the first cycle was not correlated with SN-38 in serum or with UGT1A1 genotype. No antibody responses were detected. Objective responses were observed in several indications, including metastatic triple-negative breast cancer, confirming that 10 mg/kg produced an encouraging overall response. CONCLUSIONS: Sacituzumab govitecan has a predictable pharmacokinetic profile and manageable toxicity at doses of 8 and 10 mg/kg. With objective responses and a good therapeutic index at 10 mg/kg, this dose was chosen for future development. Cancer 2017;123:3843-54.
INTRODUCTION
Antibody-drug conjugates (ADCs), comprising antibodies linked to active therapeutic agents for selected delivery of toxic payload to cancer cells, are approved for Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancers, and several new ADCs are in development that target various antigens associated with hematopoietic and solid tumors. [1] [2] [3] [4] Nearly all ADCs use drugs with picomolar toxicity, such as calicheamicin, which interchelates in DNA, or auristatin or maytansine, as microtubule inhibitors. These drugs are not used as stand-alone agents because they are highly toxic. However, when appropriately linked to antibodies, their therapeutic window is acceptable, although careful selection of the appropriate antibody and linker technology is crucial for successful clinical application.
We developed ADCs based on the well known anticancer drug SN-38, a camptothecin that is the active component of irinotecan (CPT-11), a topoisomerase I inhibitor. 5, 6 Although SN-38 has a more moderate level of potency compared with drugs used by other ADCs, preclinical testing in murine xenograft models indicated that, under optimized conditions (ie, antibody and linker selection), ADCs prepared with SN-38 were effective and had a highly favorable therapeutic window. [7] [8] [9] One of these SN-38 conjugates (company designation, IMMU-132; US Adopted Name, sacituzumab govitecan) targets Trop-2 (trophoblastic cell-surface antigen; also, termed epithelial glycoprotein-1 or EGP-1), a glycoprotein that is highly expressed by many epithelial cancers. 10, 11 Trop-2 also is present in many corresponding normal tissues, 11, 12 but studies in Cynomolgus monkeys that express crossreactive Trop-2 in similar tissues indicated only doselimiting neutropenia and gastrointestinal toxicities. 7 Because these events are typically associated with irinotecan therapy, and because there was no appreciable damage to Trop-2-expressing normal tissues, even at relatively high human equivalent doses, we surmised that either the antigen is sheltered in some manner in normal tissues or the normal tissues are less affected by the more moderately toxic SN-38.
We recently reported results from the phase 1 doseescalation study with sacituzumab govitecan (IMMU-132) in patients with diverse metastatic epithelial cancers. Patients received the drug for 2 weeks in 3-week treatment cycles. 13 Doses of 8, 10, 12, and 18 mg/kg were studied, and the maximum tolerated dose, which was assessed by tolerance to a single cycle of therapy, was determined to be 12 mg/kg. However, at this dose, there were frequent delays within or between cycles, and dose reductions were required. Therefore, for patients to receive multiple cycles of therapy with minimal delays or dose reductions, enrollment was continued at 2 lower dose levels: 8 and 10 mg/ kg. Here, we summarize the pharmacokinetic (PK) and safety assessments of IMMU-132 and examine the early efficacy evidence in patients with diverse advanced epithelial cancers.
MATERIALS AND METHODS

Eligibility and Phase 1/2 Design
Enrollment at 8 investigational sites was permitted in this registered clinical trial (NCT01631552; clinicaltrials.gov) after approval by each institutional review board, and after each participant had provided informed consent. The phase 1 dose-escalation portion was previously reported. 13 The subsequent phase 2 dose-expansion component of this single-arm, basket trial focused on the accrual of additional patients with diverse metastatic (stage IV) epithelial cancers who progressed after at least 1 prior standard therapy using the starting dose levels of 8 or 10 mg/kg on days 1 and 8 of 21-day cycles. Enrollment was performed in a sequential manner, first at the 8-mg/kg dose level and then at 10-mg/kg level. The current analysis concentrates on patients who were enrolled at starting dose levels of 8 and 10 mg/kg, including those who were at these dose levels in the phase 1 trial, 13 which accrued through April 30, 2015, with follow-up data collected through June 30, 2015, allowing sufficient time for the first response assessment to be reported for the last patient included in the analysis.
Patients were required to sign informed consent; to have an Eastern Cooperative Oncology Group performance status of 1; and to have adequate hematologic, liver, and renal function (grade 1 according to the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version 4.03). Because of the diversity of the cancer population, patients were not required to have received a prior regimen that contained a topoisomerase I inhibitor. Whenever archived tumor tissue was available, sections were processed for immunohistochemical assessment of Trop-2 13 ; however, because prior tissue microarray assessments suggested that >80% of these cancers had moderate to strong expression, 14 prescreening was not required for eligibility. The major exclusion criteria included pregnancy, Gilbert disease, intolerance to a previous irinotecan-containing therapy, known central nervous system metastases (unless stable for at least 4 weeks), or any single lesion >7 cm in greatest dimension.
Drug Administration and Supportive Medications
All treatments were given by intravenous infusion at an initial infusion rate of 50 mg/hour and were completed within 3 hours (subsequent infusions were completed within 90-120 minutes), with investigators optionally prescribing premedications (eg, diphenhydramine, acetaminophen, and dexamethasone) to reduce the risk of infusion reactions. Antiemetics and anticholinergics (eg, atropine sulfate) were permitted at the physician's discretion. Treatments were given with cycles repeated until progression or intolerance. Dosing was delayed, with or without subsequent reductions, for adverse events grade 3 (hematologic or nonhematologic). Hematopoietic growth factor support was allowed for neutropenia prophylactically after cycle 1 at the discretion of the physician. Treatment was permanently discontinued for delays >3 weeks. Physical examinations, blood counts, and chemistries were performed on the day of each planned dose. Serum biomarkers relevant to the patient's disease were followed monthly. In addition, a baseline wholeblood specimen was collected to determine uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype by gel electrophoresis using polymerase chain reaction genotyping reagents from EntroGen, Inc. (Woodland Hills, Calif).
Safety and Efficacy
Safety was assessed by using CTCAE, version 4.03. The analytical data set included any patient who received at least 1 treatment. Dose delays, defined as any delay 3 days from the expected 7-day and 14-day interval between the first and second doses or the second and third doses, respectively, were assessed in all patients who received 3 doses.
Each investigational site was responsible for radiologic measurement of target lesions and for selecting nontarget lesions of interest, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, 15 at baseline and follow-up examinations scheduled every 8 weeks, unless there was more than a 30% reduction in the sum of greatest dimension of the target lesion. An additional confirmatory assessment was made within 4 to 8 weeks, with additional follow-up occurring at 8-week intervals. The best overall response was ascribed in accordance with RECIST 1.1; however, response assessments were performed per protocol only for patients who completed at least 1 cycle (2 doses) of therapy and included patients who underwent a computed tomography assessment after starting therapy, unless there was clinical progression determined by the managing physician.
PK Analysis and Immunogenicity Testing
Seven sites participated in accruing patients for PK assessments. Blood samples were collected primarily to capture peak (30 minutes after end of infusion) and trough (before the next treatment) levels, but other patients had samples taken at several intervals after the end of the first infusion, including 30 minutes, 3 to 4 hours, and on days 1, 2, 3, and 7, so that PK parameters could be estimated. Serum was required to be separated and frozen as quickly as possible to preserve conjugate integrity. At the time of analysis, serum was thawed, and sufficient volume was removed for the determination by enzyme-linked immunosorbent assay (ELISA) of IMMU-132 (intact conjugate) and humanized antitrophoblast cell-surface antigen antibody (hRS7) immunoglobulin G (IgG), and by reversed-phase high-performance liquid chromatography for total and free concentrations of SN-38 and glucuronidated SN-38 (SN-38G). These assays have been described elsewhere. 13, 16 Free SN-38 represents the amount of SN-38 observed in the serum that was not bound to the conjugate, and total SN-38 represents bound plus free SN-38. PK parameters were estimated in patients who had at least 4 blood draws after the end of the first infusion using PK Solutions (v 2.0) Noncompartmental Pharmacokinetic Data Analysis (Summit Research Solutions, Montrose, Colo). The data were fit using a single exponential model, including the samples that best defined the clearance while maintaining a correlation exceeding 0.97 (eg, IgG clearance emphasized the later data points, whereas IMMU-132 and SN-38 emphasized the earlier data points; a minimum of 3 points were required). The area under the curve (AUC) included the area derived only from the data set (not extrapolated to infinity). Chi-square testing was performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, La Jolla, Calif).
Immunogenicity was examined in serum samples taken at baseline, before each even-numbered cycle (ie, cycles 2, 4, 6, etc), and 1 month after discontinuation of the study. Three ELISAs measured antibodies against the intact conjugate (IMMU-132), the hRS7 IgG, or SN-38. Assay sensitivity was 50 ng/mL for the intact conjugate and the hRS7 IgG and 170 ng/mL for the anti-SN-38 antibody. 13 
RESULTS
Overview
In the phase 2 dose-expansion portions of the trial, accrual through April 30, 2015, included a total of 178 patients, including 81 and 97 patients with advanced tumors treated at the starting doses of 8 and 10 mg/kg, respectively ( Table 1 ). The median number of prior therapies for all patients was 4, and most patients in each indication had received a median of 3 prior therapies. Trop-2 expression by immunohistochemistry was positive in 139 of 150 (93%) archived tissues, and 82% had moderate (21) to strong (31) expression levels (see Supporting Materials and Supporting Table 1 ; see online supporting information).
Safety and Tolerability
In total, 1998 infusions were received by 178 patients in the 8-mg/kg and 10-mg/kg groups, with a median of 9 doses received by patients in each cohort (ranges, 1-35 and 1-30 doses at 8 and 10 mg/kg, respectively), and 35 patients were continuing treatment at the cutoff date. Most patients received more than 1 cycle of treatment (>2 doses), with the exceptions that 2 patients at the 8-mg/kg dose received 2 doses and 4 received 1 dose, whereas 4 patients at the 10-mg/kg dose received only 2 doses, and another 4 received only 1 dose before dropping out. Dose interruptions occurred during 25 infusions (1.1%) in 22 patients, but all completed their infusion, except 1 who came off study because of a grade 2 infusion reaction during the 15th infusion; however, no antiantibody response was detected in serum taken 3 weeks later.
First-cycle delays occurred in 52 patients, including 22 of 77 (29%) assessable patients in the 8-mg/kg dose group and 30 of 89 (34%) in the 10-mg/kg dose group. Delay durations were most commonly between 6 and 8 days and were related mainly to grade 3 or 4 neutropenia. Regarding dose reductions, 85% of the 912 doses administered to patients who received >1 treatment of 8 mg/kg were given at the starting level, with reductions occurring in 15 of 77 patients (19%). At 10 mg/kg, 1078 doses were administered to 93 patients who received > 1 treatment, and 26 patients (28%) required a dose reduction sometime during their treatment, although an average of 75% of all doses were given at the starting dose level. Approximately 50% of all dose reductions in both groups occurred after the first or second dose (ie, in the first cycle). During the phase 2 expansion portion of the trial, investigators were permitted to use a granulocytecolony-stimulating factor cytokine after the first dose to prophylactically control subsequent neutropenia. At the time of this analysis, 18 patients in the 8-mg/kg group (22%) and 25 patients in the 10-mg/kg group (26%) had received at least 1 hematologic cytokine support treatment. Seven patients (8.6%) in the 8-mg/kg cohort left the study with an adverse event, 2 of which were considered treatment-related. Ten patients (10.3%) in the 10-mg/kg group left the study with an adverse event, of which 7 were considered treatment-related.
At the time of this analysis, adverse events for all causalities were reported in 80 of 81 (99%) and 89 of 97 (92%) patients in the 8-mg/kg and 10-mg/kg cohorts, respectively. The 10-mg/kg cohort had a somewhat higher incidence of grade 3 events, including diarrhea, neutropenia, and febrile neutropenia, than the 8-mg/kg cohort, but the overall incidences were not appreciable to warrant selecting 8 mg/kg as the starting dose ( Table 2) . None of the patients reported grade 4 diarrhea, but 6 patients (4%) with grade 3 diarrhea (1 at 8 mg/kg and 5 at 10 mg/ kg) were hospitalized. Because neutropenia was the most common reason for dose delays or reductions, we examined when the first incidence of grade 3 neutropenia occurred (Supporting Fig. 1 ; see online supporting Original Article information). As expected, a higher percentage of patients in the 10-mg/kg cohort had grade 3 neutropenia after the first dose than in the 8-mg/kg cohort (47% vs 21%, respectively), with 50% of the 8-mg/kg group and 63% of the 10-kg/mg group reporting severe neutropenia after 1 or 2 doses. The 8-mg/kg group had a slightly higher frequency after 3 doses (50% vs 42%). UGT1A1 status was available for 146 patient in the 8-mg//kg (n 5 69) and 10-mg/kg (n 5 77) IMMU-132 cohorts. Overall distribution of the *1*1, *1*28, and *28*28 haplotypes was the same as reported by others (Fig. 1) . 17 The pie chart in Figure 1 also illustrates the proportion of patients with each of the 3 haplotypes who experienced grade 3 neutropenia or various grades of diarrhea at some time during treatment. For example, 60 patients reported grade 3 neutropenia at some time during their treatment (24 [38%] , 25 [39%], and 11 [58%] with the *1*1, *1*28, and *28*28 haplotypes, respectively); however, 13 of these occurrences were reported after the start of the third cycle (5 patients in *1*1 group and 8 in the *1*28 group), whereas all 11 events occurred within the first 2 cycles for patients in the *28*28 group. Neutropenia occurred during the first cycle for 11 of 24 (46%), 11 of 25 (44%), and 6 of 11 (55%) patients in the*1*1, *1*28, and *28*28 groups, respectively. Chisquare testing indicated no significant correlation between the 3 haplotypes and severe neutropenia for the combined dose groups occurring within the first 2 cycles or at any time during treatment (P 5 .073 and P 5 .278, respectively) or for patients who only received 10 mg/kg (P 5 .9927 and P 5 .872, respectively). Grade 3 diarrhea occurring any time during treatment in patients who received IMMU-132 at 8 mg/kg and 10 mg/kg also was reported by proportionally higher numbers of patients Abbreviations: AEs, adverse events; NA, not applicable; WBC, white blood cells. a AEs were reported in 80 of 81 and 89 of 97 patients in the 8-mg/kg and 10-mg/kg groups, respectively, and included the following cancers: colorectal (19 and 10 patients, respectively), esophageal (7 and 7, respectively), endometrial (0 and 1, respectively), gastric (2 and 3, respectively), head and neck (1 and 1, respectively), hepatocellular (1 and 0, respectively), nontriple-negative breast (0 and 2, respectively), prostate (1 and 0, respectively), nonsmall cell lung (8 and 11, respectively), ovarian (4 and 0, respectively), pancreatic ductal (5 and 7, respectively), renal (0 and 1, respectively), small-cell lung (15 and 6, respectively), triple-negative breast (14 and 38, respectively), and urinary bladder (3 and 2, respectively). b Listings are ranked in descending order for all events in the 10 mg/kg cohort.
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Cancer October 1, 2017 with the *28*28 haplotype (16%) versus the other 2 haplotypes at 5% and 8%, but the overall incidence of severe diarrhea was low (10 of 146 UGT-tested patients; 6.8%), being reported in only 5, 3, and 2 patients with the *1*1, *1*28, and *28*28 haplotypes, respectively. Although chi-square testing indicated a significant correlation between the haplotypes and grade 3 diarrhea for all patients (P 5 .024), there was no significant correlation when only patients in the 10-mg/kg group were examined (P 5 .357). Table 3 summarizes the clearance kinetics of the 4 constitutive products, IMMU-132, hRS7 IgG, and SN-38 (total and free) generated from a diverse population (Supporting Table 2 ; see online supporting information). IMMU-132 cleared at a faster rate than the hRS7-unconjugated IgG, which was expected based on in vitro data demonstrating that the conjugate releases 50% of its SN-38 payload every day. 7, 14 The clearance rate for IMMU-132 by ELISA was slightly faster than that measured by total SN-38, which likely reflects the ELISA's inefficiency for detecting IMMU-132 when the substitution level becomes markedly decreased (eg, 2). Most SN-38 in serum was bound to IgG, with median total SN-38 levels in the 10 mg/kg group of 4234 and 1334 ng/mL at 30 minutes and day 1, respectively, whereas free SN-38 levels were just 95.3 ng/mL (2.3%) and 56.9 ng/mL (4.5%) at these same times, respectively ( Table 4 ). The AUC data for free SN-38 revealed that it was only approximately 2.5% of the total SN-38, indicating that most of the SN-38 in serum was bound to the IgG. Total and free SN-38 half-lives were not appreciably different, but the volume of distribution (V d ) and clearance (C L ) data indicated that free SN-38 was distributed (and eliminated) more rapidly than total SN-38, which was largely bound to the antibody. Free SN-38 levels 30 minutes after the first dose and neutropenia (nadir occurring after the first dose) were assessed in 61 patients from the 8-mg/kg and 10-mg/kg cohorts, and there was no evidence to suggest that neutropenia was correlated with the levels of free SN-38 initially in the serum (Fig. 2 and Supporting Table 3 ; see online supporting information).
PK Parameters and Immunogenicity
Total and free levels of SN-38G were similar (Table  3) , supporting earlier preclinical findings that, while bound to the IgG, SN-38 is largely protected from glucuronidation. 16 In the 10-mg/kg group, which had more data available for the evaluation of free SN-38G clearance, the AUC (mean 6 standard deviation) for the glucuronidated free SN-38G was 1.5 6 0.9 mg-hour/mL (n 5 17) versus 2.9 6 0.9 mg-hour/mL (n 5 27) for the nonglucuronidated form (average free SN-38G/free SN-38 AUC ratio 5 0.52). Peak and trough levels of IMMU-132 and hRS7 IgG were measured over the course of 7 treatments in several patients who received 8 mg/kg or 10 mg/kg, in which the starting dose was maintained and the dosing regimen was administered as planned (ie, 7-day interval within each treatment cycle and 14-day interval between cycles) (Supporting Fig. 2 ; see online supporting information). Concentrations of the IgG varied based on the interval spacing, but the overall trend revealed that peak IgG concentrations increased proportionally as more treatments continued in the 10-mg/kg dose group. Because IMMU-132 levels were essentially cleared within 3 days by the gradual release of SN-38, peak levels of the conjugate remained closely aligned with the starting dose (results not shown).
Samples from 167 patients who had at least 1 follow-up sample drawn (most had multiple follow-up samples) were assayed for an antibody response to the conjugate (either to the intact conjugate, to IgG, or to SN-38). No samples exhibited an antibody response to any component of IMMU-132. 
Efficacy
An interim objective response rate at the time of data cutoff (June 30, 2015) was determined for 4 indications, separately examining patients who received 8 mg/kg or 10 mg/kg IMMU-132 ( Fig. 3 and Supporting Table 4 ; see online supporting information). Because enrollment was not randomized, the number of patients in each of these indications was skewed to 1 or the other dose level, with a total of 56 patients at the 8-mg/kg dose level compared with 70 patients at the 10-mg/kg dose level. In the 8-mg/kg and 10-mg/kg groups, 6 and 3 patients, respectively, did not complete 1 cycle of therapy and thus were not considered assessable for response, according to the protocol. Except for colorectal cancer, the 10-mg/kg group had a more favorable objective response rate: in total, 15 of 68 (22%) assessable patients achieved an objective response, whereas only 5 of 50 (10%) assessable patients in the 8-mg/kg group achieved an objective response (Fig. 3) . In addition, the clinical benefit rate, which was calculated by combining objective responses and stable disease that lasted 4 months for lung cancers and 6 months for colorectal and triple-negative breast cancers, was higher for the 10-mg/kg group than for the 8-mg/kg group in 3 of the 4 indications.
DISCUSSION
Antibody-drug conjugates are gaining interest as an attractive approach for selectively delivering cytotoxic drugs to cancer. IMMU-132, which is composed of a moderately toxic agent, SN-38, that is used clinically in the form of irinotecan, is loaded with an average of 7.6 SN-38 molecules/IgG. 14 Most other ADCs using more potent drugs have a substitution level of about 3 or 4 molecules/IgG. 14 The higher SN-38 substitution level does not impact the PK behavior of IMMU-132 significantly 14, 18 but likely compensates for the more moderate potency of SN-38. However, the clinical trial is indicating that toxicity has been manageable in a diverse population of patients, with 10 mg/kg appearing to be an acceptable starting dose level based on safety and efficacy assessments. Like most other ADCs, IMMU-132 uses an antibody that internalizes, which is considered a key element for a successful ADC; however, unlike other conjugates that require a highly stable linker, the linker used in IMMU-132 allows slow release of SN-38, because preclinical studies indicated that this type of linker was better suited for SN-38 than a more stable type. 8, 9 Compared with irinotecan, which clears very rapidly from the serum, is poorly converted to SN-38 (estimated to be < 5%), and is susceptible to inactivation from several pathways (eg, lactone-ring conversion and glucuronidation), 6 IMMU-132 provides a protective environment for SN-38, maintaining it in its most active form until released. Studies in human tumor xenografts have indicated that IMMU-132 is able to deliver higher concentrations of SN-38 to tumors compared with irinotecan-derived SN-38 therapy. 16 This delivery advantage is likely attributed to the ADC binding to antigen within tumor and its subsequent internalization by tumor cells or local release within the tumor microenvironment of fully active SN-38. Other forms of polyethylene glycol-conjugated SN-38 or irinotecan, although enhancing the serum half-lives of their respective agents, are not bound selectively in the tumor, where the release of SN-38 could exert its maximum effect. [19] [20] [21] [22] Indeed, studies with human tumor xenografts in mice with etirinotecan pegol indicated that responses were improved compared with irinotecan; however, clinically, the extended serum half-life delayed diarrhea for more than 40 days. 22, 23 IMMU-132 also releases its SN-38 payload, but over a shorter period (approximately 90% within 3 days); and it is noteworthy that IMMU-132 results in remarkably lower SN-38G levels in the serum than those observed with irinotecan, which likely contributes to the lower incidence of severe diarrhea in patients. Thus, IMMU-132 has struck the right balance of conjugate stability with the added benefit of selective binding to the tumor to optimize the therapeutic window for SN-38 delivery.
In initial Cynomolgus monkey studies, 2 doses of 60 mg/kg given 3 days apart resulted in only transient neutropenia (a cumulative dose of 120 mg/kg is equivalent to 40 mg/kg in humans). 7 Thus, the phase 1 trial with IMMU-132 started at 8 mg/kg given on days 1 and 8 of a 21-day cycle, and 12 mg/kg was declared the maximum tolerated dose. 13 However, at 12 mg/kg, dose delays and reductions were common in subsequent cycles; therefore, the expansion study sought additional data using 8 mg/ kg, and an intermediate dose of 10 mg/kg, to determine a dose that could be better tolerated in multiple cycles. Neutropenia continued to be the most common doselimiting event, with the frequency of grade 3 events only slightly higher at the 10-mg/kg dose level versus the 8-mg/ kg dose level. Indeed, nearly 1000 doses were received in each cohort, and 75% (10 mg/kg) to 85% (8 mg/kg) of all treatments were at the same starting dose level, suggesting minimal differences in the requirement for dose reduction; and even the frequency of dose delays was similar between the 2 dose cohorts. Patients with the UGT1A1 *28*28 haplotype were somewhat more likely to experience grade 3 neutropenia than those with the *1*1 or *1*28 haplotypes; however, because approximately 40% of these patients did not experience grade 3 neutropenia, and with approximately 40% of those with the other haplotypes experiencing grade 3 neutropenia, the management of a neutropenic event is more appropriate than screening for patients who have UGT1A1 mutant types.
The incidence of grade 3 diarrhea (no grade 4 events occurred in these patients) was somewhat higher in the 10-mg/kg group (10%) and resulted in more hospitalizations compared with the 8-mg/kg group (4%). However, the frequency of severe diarrhea with IMMU-132 was Table 4 for more details of each indication (see online supporting information).
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Cancer October 1, 2017 much less than that reported with irinotecan monotherapy. [24] [25] [26] [27] Diarrhea caused by irinotecan therapy can be derived from several sources, including high concentrations of SN-38 and irinotecan (which can be converted to SN-38 by enteric bacteria) that are eliminated rapidly through the intestines and also the recycling of SN-38G through the enterohepatic circulation, with the conversion of SN-38G to SN-38 by enteric bacteria. 25 With IMMU-132, large concentrations of SN-38 are not eliminated rapidly in the intestines but, rather, are excreted more slowly over 3 days. Xie et al reported that SN-38G levels were more predictive of diarrhea in patients who received irinotecan instead of SN-38, with an AUC for SN-38G of 4.416 6 3.816 mg/mL.hour and an SN-38G/ SN-38 AUC ratio of nearly 10:1. 28 Although our sampling was sparse compared with their study, our AUC estimate for SN-38G in patients who received 10 mg/kg IMMU-132 was only 1.5 6 0.9 mg-hour/mL (n 5 17), and the AUC ratio for IMMU-132 was only 0.52, which is consistent with a lower incidence of diarrhea in IMMU-132-treated patients. Again, the patients' UGT1A1 status was not a useful predictor of severe diarrhea, and 84% of patients who had the higher risk *28*28 UGT1A1 haplotype had grade 2 diarrhea.
Thus, with no appreciable differences in safety at the 10 mg/kg dose level, with patients being able to continue at this treatment level for a similar period as the 8 mg/kg dose, and with data suggesting that 10 mg/kg IMMU-132 provides somewhat better overall response and clinical benefit rates, we concluded that further accrual to various indications would proceed at the 10-mg/kg dose level. It is important to note that safety and efficacy assessments were performed in a diverse population of patients with metastatic cancers who had received multiple and varied prior treatment regimens, including about 30% who received a topoisomerase I inhibitor (primarily patients with gastrointestinal and small cell lung cancer who received an irinotecan-containing regimen or topotecan). Nevertheless, our results suggest that 10 mg/kg is a reasonable choice for each of these indications. Having made this determination, enrollment in several indications, including triple-negative breast cancer, non-small cell lung cancer, small cell lung cancer, urinary bladder cancer, endometrial cancer, and other epithelial cancers, is continuing only at this dose. Each of these indications will be reported in more detail as their enrollment meets specific goals. A summary of the initial experience in patients with metastatic triple-negative breast cancer who received 10 mg/kg has been published. 29 Trop-2 expression in archived tissues was examined in 150 patients; however, because nearly all specimens were positive, it is not possible to conclude that the prescreening of archived tissue would sufficiently enrich patient selection. This evaluation is continuing, and additional efforts are being undertaken to obtain biopsy specimens of metastases.
Trop-2 is not present in the serum, even at low nanogram levels, as noted previously 13 ; therefore it is not surprising that the PK properties were similar between the 2 dose levels and between patients with different types of cancer. IMMU-132 levels in the serum decreased more rapidly than IgG levels, reflecting the known in vitro release of SN-38 from the conjugate when held in serum. 7 We have not yet determined which substance or factor in serum is involved in the release of SN-38 from the conjugate; however, because the clearance rates of IMMU-132 were not highly variable among patients, even with different tumor types, whatever is contributing to SN-38 release does not appear to be different among patients. Free SN-38 levels in 30-minute serum samples were similar to those reported for SN-38 in patients who received irinotecan monotherapy at their maximum serum concentration (eg, 56 6 28 ng/mL), 30 with levels at 10 mg/kg averaging 1.7-fold higher (93.4 6 43.9 ng/mL; n 5 34).
Doses of 8 to 10 mg/kg are higher than those given with the currently approved ADCs, which also are administered less frequently (eg, once every 3 weeks vs IMMU-132, which is given twice every 21 days). Modeling studies suggest that higher protein doses could aid in overcoming the "binding-site" barrier, which impedes macromolecule migration from the perivascular space within a tumor 31, 32 ; however, residual levels of the antibody could theoretically compete with subsequent ADC doses. The 10-mg/kg dosing regimen did allow more unconjugated antibody to accumulate in the serum during repeated dosing than the 8-mg/kg regimen, with the percentage increase after 7 treatments averaging 50% and 29% for the 10-kg/mg and 8-mg/kg groups, respectively. Although the microdynamics within a tumor are unknown, we hypothesize that: 1) the 2-week interval between dosing cycles reduces IgG levels in the serum sufficiently so that ADC will be at higher levels to favor its binding, and 2) the antibody internalizes quickly after binding to Trop-2, thus this dynamic will likely ensure that unoccupied Trop-2 is available on the surface of cells for ADC binding.
Another consideration is the finding that both the hRS7 antibody and IMMU-132 have antibodydependent cellular cytotoxicity, 18 which may provide an
Original Article immunotherapy mechanism alongside the cytotoxicity of SN-38. With respect to dosing frequency, preclinical studies in xenograft models indicated that twice-weekly and once-weekly dosing were preferred over once every 14 days 14, 18 ; however, the selection of dosing regimens in these models is often influenced by the rapid progression of the xenografted human tumor, particularly when a more moderately toxic drug is used. Nevertheless, the current dosing regimen is designed to maintain tumor exposure to the ADC over an extended period.
In conclusion, the current clinical results in patients with diverse metastatic solid cancers continue to indicate that sacituzumab govitecan is safe and has therapeutic activity in several metastatic solid cancer types, even after many prior lines of therapy (median 5 4 prior lines; range, 1-11 prior lines). 29, [33] [34] [35] Sacituzumab govitecan has an excellent PK profile with a low fraction of SN-38G, resulting in lower rates of diarrhea and a manageable toxicity profile. With improved responses and a good therapeutic index at 10 mg/kg, this dose was chosen for future development in patients with solid tumors, in addition to completing a phase 2 trial in patients with metastatic triplenegative breast cancer for pursuing accelerated approval after receiving Breakthrough Therapy designation from the US Food and Drug Administration. In addition, combination therapy trials with select agents are being developed based on promising preclinical results. 36 
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